According to @KLVeritas, recent FDA recommendations have been released without the new studies previously promised by the agency, sparking uncertainty about the regulatory pathway for biotech firms. As noted by @DowdEdward, this uncertainty could increase volatility not only in traditional biotech stocks but also in related bio-pharma crypto tokens, as traders weigh regulatory risks and market sentiment shifts (Source: Twitter/@KLVeritas, May 23, 2025). Market participants should monitor FDA communications closely, as regulatory clarity often drives short-term trading opportunities and liquidity surges in both stock and crypto sectors.